Abstract: Provided are specific leukotriene synthesis inhibitor compounds and pharmaceutical compositions comprising the compounds and methods of using the compounds and the pharmaceutical compositions in treating, for example, inflammatory diseases or conditions.

Abstract: The present invention relates to an isoindolin-1-on derivative, a method for preparing same, and a pharmaceutical composition comprising same as an effective component for preventing or treating tumors, wherein the isoindolin-1-on derivative exhibits a high inhibitory effect on EGFR mutations, and thus can be beneficially used for the treatment of EGFR-mutated tumors, and the isoindolin-1-on derivative exhibits a significant synergistic effect when co-administered, and thus can be beneficially used in concomitant therapy.

Abstract: The present invention relates to compositions, methods and kits for the treatment of respiratory disease. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment or prevention of exacerbations of asthma and chronic obstructive pulmonary disease. The present invention provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1, thereby treating or preventing a respiratory disease in a subject. The present invention also provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of ALK5, thereby treating or preventing a respiratory disease in a subject, wherein the inhibitor is administered directly to the airway and/or lungs.

Abstract: The present invention relates to metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine. These metabolites may act as RAGE antagonists. These metabolites may also be useful in assays to measure the presence or amount of one or more metabolites of the parent compound in a sample.

Abstract: The present invention relates to novel crystalline salt forms of mesembrine, also known as 3a-(3,4-dimethoxyphenyl)-octahydro-1-methy-6H-indol-6-one. Mesembrine has the chemical formula C17H23NO3. The invention further relates to the preparation of a novel crystalline salt of mesembrine and to the use of the mesembrine salt as a medicament. In one embodiment the novel crystalline salt form of mesembrine is mesembrine besylate salt.

Abstract: Disclosed are pyrazole compounds represented by formula (I), pharmaceutical compositions containing such compounds, a method for preparing such compounds, and use of the pyrazole compounds and the pharmaceutical compositions. Such compounds are useful for inhibiting IRAK family kinases, and also useful for treating diseases caused by IRAK family kinases, such as autoimmune diseases, inflammatory diseases and cancers.

Abstract: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: An 4,5-bis(4-bromophenyl)-1-hexyl-2-(4-hydroxy-3-dimethoxyphenyl)-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The present invention generally relates to various dibenzothiophene compounds, processes for preparing these compounds, and uses of these compounds. The present invention also relates to cell imaging agents comprising one or more of the dibenzothiophene compounds and processes for imaging a cell using the compounds. The present invention further relates to methods of producing ground state atomic oxygen.

Abstract: The disclosure relates to the field of fluorescent dyes, and provides a fluorescent dye with phenanthridine and benzothiazole conjugated. The fluorescent dye has the following structural formula: Through the above technical solution, the problems in the prior art that the fluorescent dye is susceptible to interference from other charged substances in a solution when detecting DNA so as not to be simultaneously applied to a blue light meter and an ultraviolet gel imager are solved.

Abstract: Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.

Abstract: A method for preparing isophorone diisocyanate by (1) reacting isophorone with hydrogen cyanide in the presence of a catalyst to obtain isophorone nitrile; (2) reacting the isophorone nitrile obtained in step (1) with ammonia gas and hydrogen in the presence of a catalyst to obtain isophorone diamine; and (3) subjecting the isophorone diamine to a phosgenation reaction to obtain the isophorone diisocyanate, wherein the content of impurities containing a secondary amine group in the isophorone diamine that undergoes the phosgenation reaction in step (3) is ?0.5 wt. The method reduces the content of hydrolyzed chlorine in the isophorone diisocyanate product, improves the yellowing resistance of the product, and the harm due to presence of hydrolyzed chlorine in the product is reduced.

Abstract: The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, including an anhydrous crystalline form, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.

Abstract: Provided are vitamin D3 derivatives of formula (I), pharmaceutical compositions thereof, and pharmaceutical or medical uses thereof for treating metabolic disease, a liver disease, obesity, diabetes, cardiovascular disease, or cancer in a patient in need thereof.

Abstract: The present invention relates to the technical field of medicine, and particularly to a lycorine derivative of Formula (I), and a pharmaceutically acceptable salt, a preparation method, a pharmaceutical composition and use thereof. The lycorine derivative has obvious antiviral activity and is useful in the treatment of viral diseases such as hand-foot-mouth disease.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Abstract: The invention provides a compound of formula I: or a salt thereof, wherein R1-R4 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful in immunotherapy as a potential treatment, or co-treatment, for cancer or infectious diseases.

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:

Abstract: Hepatitis C virus (HCV) is a human pathogen with high morbidity. The HCV NS3/4A protease is essential for viral replication and is one of top three drug targets. A number of drugs have been developed but drug resistant mutant strains emerged. Here we screened and synthesized of novel class of small molecules of Formula I or Formula IA based on tryptophan derivative scaffold as HCV NS3/4A protease inhibitors that is active against both wild type and mutant form of the protease. Only the docking hits with a binding pose that is not affected by the most frequent mutations in the active site were selected for experimental validation. The antiviral activities were evaluated by replicon and enzymatic assays. Twenty-two compounds in this series were found to inhibit HCV with EC50 values ranging between 0.64 to 63 ?M with compound 22 being the most active of this series. In protease assays, 22 had a comparable inhibition profile for the common mutant HCV GT1b D168A and the wild type enzyme.